-
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (EVOMELA®).
-
Bringing life-changing therapeutics to China and the world.
June 10, 2021
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.
March 8, 2021
Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in cancer, and CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, today announced they have entered an exclusive licensing agreement for the development and commercialization of CB-5339, a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong and Macau.
Press Release
May 27, 2021
Press Release
May 13, 2021
CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.
EVOMELA® (melphalan) for Injection, ZEVALIN® (ibritumomab tiuxetan), and MARQIBO® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.
© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.
